BCPC

Balchem Corp

Add to Watchlist

Advanced Chart

148.820

-0.38(-0.255%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

150.065

Open

149.960

VWAP

149.10

Vol

268.32K

Mkt Cap

4.85B

Low

148.480

Amount

40.01M

EV/EBITDA(TTM)

20.98

Total Shares

32.42M

5.01B

EV/OCF(TTM)

27.06

P/S(TTM)

5.07

Balchem Corporation develops, manufactures, distributes and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition and industrial markets. Its segments include Human Nutrition and Health (HNH), Animal Nutrition and Health (ANH), and Specialty Products. The HNH segment provides human grade choline nutrients and mineral amino acid chelated products for nutrition and health applications. This segment also manufactures specialty vitamin K2, which plays a role in the human body for bone health, heart health and immunity, and methylsulfonylmethane (MSM). The ANH segment provides nutritional products derived from its microencapsulation and chelation technologies in addition to the nutrient choline chloride. The Specialty Products segment re-packages and distributes a number of gases and chemicals for various uses by its customers, notably ethylene oxide, propylene oxide, and ammonia.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2025Q3

FY2025Q2

258.37M

+7.65%

1.295

+14.6%

257.65M

+7.38%

1.315

+16.37%

250.31M

+6.93%

1.250

+14.68%

Estimates Revision

The market is revising Downward the revenue expectations for Balchem Corporation (BCPC) for FY2025, with the revenue forecasts being adjusted by -1.51% over the past three months. During the same period, the stock price has changed by -3.14%.

Revenue Estimates for FY2025

Revise Downward

-1.51%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+1.5%

In Past 3 Month

Stock Price

Go Down

-3.14%

In Past 3 Month

1 Analyst Rating

20.95% Upside

Wall Street analysts forecast BCPC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BCPC is 180.00 USD with a low forecast of 180.00 USD and a high forecast of 180.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

20.95% Upside

Current: 148.820

Low

180.00

Averages

180.00

High

180.00

20.95% Upside

Current: 148.820

Low

180.00

Averages

180.00

High

180.00

HC Wainwright & Co.

Raghuram Selvaraju

Strong Buy

Reiterates

$190

2025-02-24

Reason

HC Wainwright & Co.

Raghuram Selvaraju

Price Target

$190

2025-02-24

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Raghuram Selvaraju

Strong Buy

Maintains

$185 → $190

2024-11-04

Reason

HC Wainwright & Co.

Raghuram Selvaraju

Price Target

$185 → $190

2024-11-04

Maintains

Strong Buy

Reason

HC Wainwright & Co.

Raghuram Selvaraju

Strong Buy

Maintains

$170 → $185

2024-07-31

Reason

HC Wainwright & Co.

Raghuram Selvaraju

Price Target

$170 → $185

2024-07-31

Maintains

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Balchem Corp (BCPC.O) is 28.75, compared to its 5-year average forward P/E of 33.30. For a more detailed relative valuation and DCF analysis to assess Balchem Corp 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Undervalued

5Y Average PE

33.30

Current PE

28.75

Overvalued PE

36.46

Undervalued PE

30.13

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Undervalued

5Y Average EV/EBITDA

21.15

Current EV/EBITDA

18.89

Overvalued EV/EBITDA

23.12

Undervalued EV/EBITDA

19.18

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

4.88

Current PS

4.69

Overvalued PS

5.50

Undervalued PS

4.26